C
ResMed Inc.
RMD
$220.22
-$5.57-2.47%
C
Hold
1/16/2025Upgraded
ResMed Inc. (RMD) was upgraded to C+ from C on 1/16/2025 due to an increase in the volatility index and valuation index.
ResMed Inc. (RMD) was upgraded to C+ from C on 1/16/2025 due to an increase in the volatility index and valuation index.
C
Hold
12/26/2024Downgrade
ResMed Inc. (RMD) was downgraded to C from C+ on 12/26/2024 due to a decline in the growth index, volatility index and efficiency index. Operating cash flow declined 26.03% from $440.11M to $325.54M.
ResMed Inc. (RMD) was downgraded to C from C+ on 12/26/2024 due to a decline in the growth index, volatility index and efficiency index. Operating cash flow declined 26.03% from $440.11M to $325.54M.
C
Hold
9/30/2024Upgraded
ResMed Inc. (RMD) was upgraded to C+ from C on 9/30/2024 due to a noticeable increase in the total return index, growth index and volatility index. Operating cash flow increased 9.47% from $402.03M to $440.11M, total revenue increased 2.19% from $1.2B to $1.22B, and EBIT increased 1.77% from $374.58M to $381.22M.
ResMed Inc. (RMD) was upgraded to C+ from C on 9/30/2024 due to a noticeable increase in the total return index, growth index and volatility index. Operating cash flow increased 9.47% from $402.03M to $440.11M, total revenue increased 2.19% from $1.2B to $1.22B, and EBIT increased 1.77% from $374.58M to $381.22M.
C
Hold
2/21/2024Upgraded
ResMed Inc. (RMD) was upgraded to C from C- on 2/21/2024 due to an increase in the volatility index and total return index.
ResMed Inc. (RMD) was upgraded to C from C- on 2/21/2024 due to an increase in the volatility index and total return index.
C
Hold
1/4/2024Upgraded
ResMed Inc. (RMD) was upgraded to C- from D+ on 1/4/2024 due to an increase in the total return index and volatility index.
ResMed Inc. (RMD) was upgraded to C- from D+ on 1/4/2024 due to an increase in the total return index and volatility index.
D
Sell
11/9/2023Downgrade
ResMed Inc. (RMD) was downgraded to D+ from C- on 11/9/2023 due to a decline in the total return index, volatility index and efficiency index. Net income declined 4.46% from $229.66M to $219.42M.
ResMed Inc. (RMD) was downgraded to D+ from C- on 11/9/2023 due to a decline in the total return index, volatility index and efficiency index. Net income declined 4.46% from $229.66M to $219.42M.
C
Hold
9/8/2023Downgrade
ResMed Inc. (RMD) was downgraded to C- from C on 9/8/2023 due to a noticeable decline in the growth index, volatility index and total return index. Operating cash flow declined 15.97% from $282.57M to $237.44M, EBIT declined 4.8% from $300.67M to $286.24M, and earnings per share declined from $1.58 to $1.5606.
ResMed Inc. (RMD) was downgraded to C- from C on 9/8/2023 due to a noticeable decline in the growth index, volatility index and total return index. Operating cash flow declined 15.97% from $282.57M to $237.44M, EBIT declined 4.8% from $300.67M to $286.24M, and earnings per share declined from $1.58 to $1.5606.
C
Hold
8/4/2023Downgrade
ResMed Inc. (RMD) was downgraded to C from C+ on 8/4/2023 due to a decline in the total return index and volatility index.
ResMed Inc. (RMD) was downgraded to C from C+ on 8/4/2023 due to a decline in the total return index and volatility index.
C
Hold
8/3/2023Downgrade
ResMed Inc. (RMD) was downgraded to C+ from B- on 8/3/2023 due to a decline in the growth index, efficiency index and total return index.
ResMed Inc. (RMD) was downgraded to C+ from B- on 8/3/2023 due to a decline in the growth index, efficiency index and total return index.
B
Buy
7/19/2023Upgraded
ResMed Inc. (RMD) was upgraded to B- from C+ on 7/19/2023 due to a substantial increase in the growth index, solvency index and valuation index. Operating cash flow increased 119.66% from $128.64M to $282.57M, debt to equity declined from 0.49 to 0.41, and total revenue increased 8.04% from $1.03B to $1.12B.
ResMed Inc. (RMD) was upgraded to B- from C+ on 7/19/2023 due to a substantial increase in the growth index, solvency index and valuation index. Operating cash flow increased 119.66% from $128.64M to $282.57M, debt to equity declined from 0.49 to 0.41, and total revenue increased 8.04% from $1.03B to $1.12B.
C
Hold
1/30/2023Upgraded
ResMed Inc. (RMD) was upgraded to C+ from C on 1/30/2023 due to an increase in the volatility index, efficiency index and growth index. Operating cash flow increased 188.02% from $44.66M to $128.64M, total capital increased 30.11% from $4.36B to $5.68B, and total revenue increased 8.78% from $950.29M to $1.03B.
ResMed Inc. (RMD) was upgraded to C+ from C on 1/30/2023 due to an increase in the volatility index, efficiency index and growth index. Operating cash flow increased 188.02% from $44.66M to $128.64M, total capital increased 30.11% from $4.36B to $5.68B, and total revenue increased 8.78% from $950.29M to $1.03B.
C
Hold
7/13/2022Downgrade
ResMed Inc. (RMD) was downgraded to C from C+ on 7/13/2022 due to a decline in the total return index, valuation index and volatility index.
ResMed Inc. (RMD) was downgraded to C from C+ on 7/13/2022 due to a decline in the total return index, valuation index and volatility index.
C
Hold
6/28/2022Upgraded
ResMed Inc. (RMD) was upgraded to C+ from C on 6/28/2022 due to an increase in the volatility index and valuation index.
ResMed Inc. (RMD) was upgraded to C+ from C on 6/28/2022 due to an increase in the volatility index and valuation index.
C
Hold
6/13/2022Downgrade
ResMed Inc. (RMD) was downgraded to C from C+ on 6/13/2022 due to a substantial decline in the growth index, total return index and volatility index. Operating cash flow declined 46.59% from $219.88M to $117.44M, earnings per share declined from $1.37 to $1.22, and EBIT declined 5.81% from $248.71M to $234.27M.
ResMed Inc. (RMD) was downgraded to C from C+ on 6/13/2022 due to a substantial decline in the growth index, total return index and volatility index. Operating cash flow declined 46.59% from $219.88M to $117.44M, earnings per share declined from $1.37 to $1.22, and EBIT declined 5.81% from $248.71M to $234.27M.
C
Hold
11/3/2021Downgrade
ResMed Inc. (RMD) was downgraded to C+ from B- on 11/3/2021 due to a noticeable decline in the total return index, growth index and efficiency index. Operating cash flow declined 128.98% from $226.53M to -$65.66M.
ResMed Inc. (RMD) was downgraded to C+ from B- on 11/3/2021 due to a noticeable decline in the total return index, growth index and efficiency index. Operating cash flow declined 128.98% from $226.53M to -$65.66M.
B
Buy
8/18/2021Upgraded
ResMed Inc. (RMD) was upgraded to B- from C on 8/18/2021 due to a significant increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.54 to $1.3299, operating cash flow increased 15.41% from $196.28M to $226.53M, and the quick ratio increased from 0.9 to 1.04.
ResMed Inc. (RMD) was upgraded to B- from C on 8/18/2021 due to a significant increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.54 to $1.3299, operating cash flow increased 15.41% from $196.28M to $226.53M, and the quick ratio increased from 0.9 to 1.04.
C
Hold
5/3/2021Downgrade
ResMed Inc. (RMD) was downgraded to C from B on 5/3/2021 due to a significant decline in the growth index, valuation index and total return index. Earnings per share declined from $1.23 to -$0.54, EBIT declined 5.18% from $235.62M to $223.43M, and total revenue declined 3.91% from $800.01M to $768.77M.
ResMed Inc. (RMD) was downgraded to C from B on 5/3/2021 due to a significant decline in the growth index, valuation index and total return index. Earnings per share declined from $1.23 to -$0.54, EBIT declined 5.18% from $235.62M to $223.43M, and total revenue declined 3.91% from $800.01M to $768.77M.
B
Buy
6/24/2020Upgraded
ResMed Inc. (RMD) was upgraded to B from B- on 6/24/2020 due to an increase in the total return index.
ResMed Inc. (RMD) was upgraded to B from B- on 6/24/2020 due to an increase in the total return index.
B
Buy
6/4/2020Downgrade
ResMed Inc. (RMD) was downgraded to B- from B on 6/4/2020 due to a substantial decline in the total return index and volatility index.
ResMed Inc. (RMD) was downgraded to B- from B on 6/4/2020 due to a substantial decline in the total return index and volatility index.
B
Buy
4/22/2020Upgraded
ResMed Inc. (RMD) was upgraded to B from B- on 4/22/2020 due to an increase in the total return index, solvency index and volatility index.
ResMed Inc. (RMD) was upgraded to B from B- on 4/22/2020 due to an increase in the total return index, solvency index and volatility index.
B
Buy
4/7/2020Downgrade
ResMed Inc. (RMD) was downgraded to B- from B on 4/7/2020 due to a large decline in the valuation index, volatility index and growth index. Operating cash flow declined 56.93% from $162.36M to $69.93M.
ResMed Inc. (RMD) was downgraded to B- from B on 4/7/2020 due to a large decline in the valuation index, volatility index and growth index. Operating cash flow declined 56.93% from $162.36M to $69.93M.
B
Buy
3/14/2019Downgrade
ResMed Inc. (RMD) was downgraded to B from B+ on 3/14/2019 due to a decline in the volatility index and total return index.
ResMed Inc. (RMD) was downgraded to B from B+ on 3/14/2019 due to a decline in the volatility index and total return index.
B
Buy
2/1/2019Upgraded
ResMed Inc. (RMD) was upgraded to B+ from B- on 2/1/2019 due to a significant increase in the growth index, valuation index and dividend index. Operating cash flow increased 169.06% from $48.12M to $129.47M, earnings per share increased from $0.73 to $0.86, and EBIT increased 13.23% from $144.13M to $163.2M.
ResMed Inc. (RMD) was upgraded to B+ from B- on 2/1/2019 due to a significant increase in the growth index, valuation index and dividend index. Operating cash flow increased 169.06% from $48.12M to $129.47M, earnings per share increased from $0.73 to $0.86, and EBIT increased 13.23% from $144.13M to $163.2M.
B
Buy
9/4/2018Downgrade
ResMed Inc. (RMD) was downgraded to B- from B on 9/4/2018 due to a substantial decline in the growth index, efficiency index and valuation index. Total capital declined 18.65% from $2.88B to $2.34B, operating cash flow declined 13.19% from $149.08M to $129.42M, and net income declined 0.29% from $110.13M to $109.81M.
ResMed Inc. (RMD) was downgraded to B- from B on 9/4/2018 due to a substantial decline in the growth index, efficiency index and valuation index. Total capital declined 18.65% from $2.88B to $2.34B, operating cash flow declined 13.19% from $149.08M to $129.42M, and net income declined 0.29% from $110.13M to $109.81M.
B
Buy
4/30/2018Upgraded
ResMed Inc. (RMD) was upgraded to B from C+ on 4/30/2018 due to a significant increase in the growth index, solvency index and efficiency index. Net income increased 1,055.93% from $9.53M to $110.13M, earnings per share increased from $0.0668 to $0.76, and the quick ratio increased from 0.99 to 2.61.
ResMed Inc. (RMD) was upgraded to B from C+ on 4/30/2018 due to a significant increase in the growth index, solvency index and efficiency index. Net income increased 1,055.93% from $9.53M to $110.13M, earnings per share increased from $0.0668 to $0.76, and the quick ratio increased from 0.99 to 2.61.
C
Hold
1/25/2018Downgrade
ResMed Inc. (RMD) was downgraded to C+ from B on 1/25/2018 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 88.94% from $86.13M to $9.53M, earnings per share declined from $0.6 to $0.0668, and total capital declined 0.97% from $3.07B to $3.04B.
ResMed Inc. (RMD) was downgraded to C+ from B on 1/25/2018 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 88.94% from $86.13M to $9.53M, earnings per share declined from $0.6 to $0.0668, and total capital declined 0.97% from $3.07B to $3.04B.
B
Buy
2/22/2017Upgraded
ResMed Inc. (RMD) was upgraded to B from B- on 2/22/2017 due to a large increase in the total return index, growth index and volatility index. Operating cash flow increased 39.02% from $86.24M to $119.9M, EBIT increased 27.34% from $94.15M to $119.88M, and total revenue increased 13.95% from $465.45M to $530.4M.
ResMed Inc. (RMD) was upgraded to B from B- on 2/22/2017 due to a large increase in the total return index, growth index and volatility index. Operating cash flow increased 39.02% from $86.24M to $119.9M, EBIT increased 27.34% from $94.15M to $119.88M, and total revenue increased 13.95% from $465.45M to $530.4M.
B
Buy
1/10/2017Upgraded
ResMed Inc. (RMD) was upgraded to B- from C on 1/10/2017 due to a significant increase in the valuation index, dividend index and solvency index.
ResMed Inc. (RMD) was upgraded to B- from C on 1/10/2017 due to a significant increase in the valuation index, dividend index and solvency index.
C
Hold
10/28/2016Downgrade
ResMed Inc. (RMD) was downgraded to C from C+ on 10/28/2016 due to a major decline in the growth index, total return index and efficiency index. Operating cash flow declined 44.81% from $156.27M to $86.24M, EBIT declined 24.34% from $124.44M to $94.15M, and earnings per share declined from $0.0662 to $0.054.
ResMed Inc. (RMD) was downgraded to C from C+ on 10/28/2016 due to a major decline in the growth index, total return index and efficiency index. Operating cash flow declined 44.81% from $156.27M to $86.24M, EBIT declined 24.34% from $124.44M to $94.15M, and earnings per share declined from $0.0662 to $0.054.
C
Hold
9/29/2016Downgrade
ResMed Inc. (RMD) was downgraded to C+ from B- on 9/29/2016 due to a decline in the total return index and volatility index.
ResMed Inc. (RMD) was downgraded to C+ from B- on 9/29/2016 due to a decline in the total return index and volatility index.
B
Buy
8/15/2016Upgraded
ResMed Inc. (RMD) was upgraded to B- from C+ on 8/15/2016 due to a large increase in the growth index, total return index and efficiency index. Total capital increased 36.07% from $2.11B to $2.87B, operating cash flow increased 27.94% from $122.15M to $156.27M, and EBIT increased 15.31% from $107.91M to $124.44M.
ResMed Inc. (RMD) was upgraded to B- from C+ on 8/15/2016 due to a large increase in the growth index, total return index and efficiency index. Total capital increased 36.07% from $2.11B to $2.87B, operating cash flow increased 27.94% from $122.15M to $156.27M, and EBIT increased 15.31% from $107.91M to $124.44M.
C
Hold
7/25/2016Upgraded
ResMed Inc. (RMD) was upgraded to C+ from C on 7/25/2016 due to a large increase in the total return index, volatility index and solvency index. The quick ratio increased from 3.73 to 3.76.
ResMed Inc. (RMD) was upgraded to C+ from C on 7/25/2016 due to a large increase in the total return index, volatility index and solvency index. The quick ratio increased from 3.73 to 3.76.
C
Hold
3/11/2016Downgrade
ResMed Inc. (RMD) was downgraded to C from C+ on 3/11/2016 due to a decline in the volatility index and total return index.
ResMed Inc. (RMD) was downgraded to C from C+ on 3/11/2016 due to a decline in the volatility index and total return index.
C
Hold
10/30/2015Upgraded
ResMed Inc. (RMD) was upgraded to C+ from C on 10/30/2015 due to an increase in the growth index and volatility index. Operating cash flow increased 22.44% from $99.7M to $122.07M.
ResMed Inc. (RMD) was upgraded to C+ from C on 10/30/2015 due to an increase in the growth index and volatility index. Operating cash flow increased 22.44% from $99.7M to $122.07M.
C
Hold
9/21/2015Downgrade
ResMed Inc. (RMD) was downgraded to C from C+ on 9/21/2015 due to a large decline in the volatility index.
ResMed Inc. (RMD) was downgraded to C from C+ on 9/21/2015 due to a large decline in the volatility index.
C
Hold
8/7/2015Upgraded
ResMed Inc. (RMD) was upgraded to C+ from C on 8/7/2015 due to an increase in the growth index, efficiency index and solvency index. Debt to equity declined from 0.3 to 0.19, operating cash flow increased 9.63% from $90.94M to $99.7M, and total revenue increased 7.23% from $422.5M to $453.06M.
ResMed Inc. (RMD) was upgraded to C+ from C on 8/7/2015 due to an increase in the growth index, efficiency index and solvency index. Debt to equity declined from 0.3 to 0.19, operating cash flow increased 9.63% from $90.94M to $99.7M, and total revenue increased 7.23% from $422.5M to $453.06M.
C
Hold
6/29/2015Downgrade
ResMed Inc. (RMD) was downgraded to C from C+ on 6/29/2015 due to a large decline in the total return index.
ResMed Inc. (RMD) was downgraded to C from C+ on 6/29/2015 due to a large decline in the total return index.
C
Hold
6/12/2015Downgrade
ResMed Inc. (RMD) was downgraded to C+ from A- on 6/12/2015 due to a significant decline in the valuation index, total return index and dividend index.
ResMed Inc. (RMD) was downgraded to C+ from A- on 6/12/2015 due to a significant decline in the valuation index, total return index and dividend index.
A
Buy
5/1/2015Downgrade
ResMed Inc. (RMD) was downgraded to A- from A+ on 5/1/2015 due to a large decline in the growth index, volatility index and valuation index. Operating cash flow declined 14.21% from $106M to $90.94M, EBIT declined 3% from $109.15M to $105.87M, and total revenue declined 0.11% from $422.95M to $422.5M.
ResMed Inc. (RMD) was downgraded to A- from A+ on 5/1/2015 due to a large decline in the growth index, volatility index and valuation index. Operating cash flow declined 14.21% from $106M to $90.94M, EBIT declined 3% from $109.15M to $105.87M, and total revenue declined 0.11% from $422.95M to $422.5M.
A
Buy
1/30/2015Upgraded
ResMed Inc. (RMD) was upgraded to A+ from B+ on 1/30/2015 due to a major increase in the total return index, growth index and solvency index. Operating cash flow increased 22.49% from $86.54M to $106M, EBIT increased 15.28% from $94.68M to $109.15M, and total revenue increased 11.19% from $380.4M to $422.95M.
ResMed Inc. (RMD) was upgraded to A+ from B+ on 1/30/2015 due to a major increase in the total return index, growth index and solvency index. Operating cash flow increased 22.49% from $86.54M to $106M, EBIT increased 15.28% from $94.68M to $109.15M, and total revenue increased 11.19% from $380.4M to $422.95M.
B
Buy
1/22/2015Downgrade
ResMed Inc. (RMD) was downgraded to B+ from A- on 1/22/2015 due to a decline in the valuation index and dividend index.
ResMed Inc. (RMD) was downgraded to B+ from A- on 1/22/2015 due to a decline in the valuation index and dividend index.
A
Buy
1/2/2015Upgraded
ResMed Inc. (RMD) was upgraded to A- from B+ on 1/2/2015 due to an increase in the total return index and volatility index.
ResMed Inc. (RMD) was upgraded to A- from B+ on 1/2/2015 due to an increase in the total return index and volatility index.
B
Buy
12/17/2014Downgrade
ResMed Inc. (RMD) was downgraded to B+ from A- on 12/17/2014 due to a large decline in the growth index, total return index and valuation index. Operating cash flow declined 25.13% from $115.58M to $86.54M, EBIT declined 9.67% from $104.81M to $94.68M, and total revenue declined 8.38% from $415.21M to $380.4M.
ResMed Inc. (RMD) was downgraded to B+ from A- on 12/17/2014 due to a large decline in the growth index, total return index and valuation index. Operating cash flow declined 25.13% from $115.58M to $86.54M, EBIT declined 9.67% from $104.81M to $94.68M, and total revenue declined 8.38% from $415.21M to $380.4M.
A
Buy
4/28/2014Upgraded
ResMed Inc. (RMD) was upgraded to A- from B+ on 4/28/2014 due to an increase in the volatility index.
ResMed Inc. (RMD) was upgraded to A- from B+ on 4/28/2014 due to an increase in the volatility index.
B
Buy
4/22/2014Upgraded
ResMed Inc. (RMD) was upgraded to B+ from C+ on 4/22/2014 due to a significant increase in the valuation index and dividend index.
ResMed Inc. (RMD) was upgraded to B+ from C+ on 4/22/2014 due to a significant increase in the valuation index and dividend index.
NYSE
03/12/2025 4:00PM Eastern
Quotes delayed
